Glenmark Pharmaceuticals Limited Max Pain Analysis
What is Max Pain?
Max Pain theory states the underlying gravitates toward the strike where option writers face minimum collective loss at expiry. For GLENMARK, that strike is ₹2,160. Spot at ₹2,229 is 3.19% above max pain — possible downward gravitational pull into expiry.
Max Pain Level
The max pain strike for Glenmark Pharmaceuticals Limited is ₹2160, where option sellers incur the least total loss at expiry. This level acts as a magnet in the final days as writer positioning influences price action.
Spot vs Max Pain Gap
The spot price at ₹2229 sits 3.19% above the max pain, indicating a downward pull toward ₹2160 as expiry nears. This gap suggests underlying pressure for the stock to drift lower to maximize writer profitability.
Shift Signal
The max pain level has remained unchanged from the previous day, signaling stable writer positioning across strikes. Minimal shift reflects balanced call and put writing activity near ₹2160.
Expiry Bias
A downward drift is expected toward ₹2160, supported by the proximity to the second-lowest pain level at ₹2180 reinforcing resistance. The bias strengthens as expiry draws within five days, when price sensitivity to open interest peaks.
Trader Note
With 7 days to expiry, premium decay strategies are not yet optimal—wait until daysToExpiry ≤ 5 for short option plays favoring the ₹2160 zone.
Data as of 2026-04-21